Quick Recap
Neurology System, Protocol 8/12. Neuromuscular respiratory failure framework shared with Myasthenic Crisis (next protocol).
1. Definition
GBS = a group of acute immune-mediated polyradiculoneuropathies, distinguished by clinical/electrophysiologic subtype. Most common US/European subtype: AIDP (acute inflammatory demyelinating polyradiculoneuropathy) — acute ascending paralysis + paresthesias, typically following an upper respiratory or diarrheal illness (antecedent infection in the majority of cases). Progresses to quadriplegia with cranial nerve involvement in many cases. Respiratory failure requiring mechanical ventilation occurs in ~20%. Autonomic dysfunction is common. Monophasic course — maximal disability by definition occurs within 4 weeks of onset (usually within 2 weeks) — this defines the expected trajectory and distinguishes GBS from relapsing/chronic mimics like CIDP.
2. Diagnostic Evaluation
Neurologic exam focus: eye movements, facial/bulbar strength, limb strength, reflexes — track serially given the progressive, often rapidly progressive nature of GBS, not just at initial presentation.
Atypical features should prompt mimic evaluation (spinal cord lesion, etc.) via MRI spine with and without contrast — nerve root enhancement is a fairly common, supportive GBS finding.
Lumbar puncture: look for albuminocytologic dissociation (elevated CSF protein WITHOUT leukocytosis) — protein elevation may be ABSENT early in the course; repeat LP if diagnosis remains in question and initial LP is unrevealing. CSF leukocytosis (>10 WBC, definitely >50 WBC) should prompt evaluation for GBS MIMICS (HIV, West Nile virus, CMV, sarcoidosis, neoplasm) rather than accepted as consistent with GBS itself.
EMG/NCS: obtain in initial evaluation, but can be normal or show only subtle abnormalities EARLY on — a normal early study does NOT exclude GBS; serial studies help differentiate subtypes over time.
Emerging marker: serum neurofilament light chain shows growing evidence for early diagnostic/prognostic utility in acute axonal injury detection.
3. Differential Diagnosis — Distinguishing Features Table (shared framework with Myasthenic Crisis)
Condition | Distinguishing features | EMG/NCS |
GBS / subacute CIDP | Absent reflexes, distal AND proximal weakness, ASCENDING progression, elevated CSF protein (esp. after day 7) | Reduced MUP recruitment, early loss of F waves; demyelinating features appear later |
Myasthenia gravis | FLUCTUATING weakness (eyelids, extraocular, nasal dysarthria), limb weakness worst in triceps/finger extensors | Decrement on repetitive nerve stimulation; standard EMG usually normal |
ALS | Chronic course until an inciting event (aspiration/pneumonia); notably SPARES the eyes until very late; hyperreflexia | Active + chronic denervation across multiple body regions |
Immune myopathies | Symmetric, PROXIMAL > distal weakness; oculobulbar function relatively spared | Small, short-duration myopathic motor units; membrane irritability |
Botulism | Predominantly children; DESCENDING weakness; autonomic symptoms | Small CMAP amplitudes with increment post-exercise/fast RNS; membrane irritability |
Key pattern-recognition pearl: ASCENDING weakness = GBS; DESCENDING weakness = botulism; FLUCTUATING/fatigable weakness = myasthenia gravis.
4. Respiratory Failure Risk Assessment
Erasmus GBS Respiratory Insufficiency Score (EGRIS): validated to predict respiratory failure within the first week of illness, available via online calculators — use proactively rather than waiting for overt respiratory distress to appear.
Nearly HALF of patients requiring ventilation will go on to need tracheostomy — set expectations early with patients/families about the likely duration and trajectory of ventilator dependence.
Intubation timing principle: if the patient is progressively worsening and has NOT yet reached their nadir, a trial of NIV/BiPAP is UNLIKELY to avoid intubation — intubate early/prophylactically rather than waiting for NIV to fail (this differs from the Myasthenic Crisis approach where NIV trial is more often reasonable — see that protocol for the contrast).
5. Immediate Stabilization (ABCDE)
Airway/Breathing: per Section 4 — early/prophylactic intubation favored over a prolonged NIV trial in a patient still progressing toward nadir.
AVOID neuromuscular blocking agents: depolarizing agents (succinylcholine) can provoke LETHAL HYPERKALEMIA in patients with denervation, a real risk in axonal GBS variants specifically — avoid succinylcholine for RSI in suspected/confirmed GBS.
Circulation — Autonomic dysfunction management:
- Monitor closely for ileus, constipation, urinary retention, labile blood pressures, and cardiac arrhythmias
- Exercise caution treating blood pressure given potential lability — aggressive antihypertensive therapy can precipitate profound hypotension in a dysautonomic patient
- Keep atropine at the bedside — suctioning can induce vagally-mediated bradycardia in these patients, a recognized and preventable crisis trigger
Checklist:
6. Evidence-Based Treatment
As soon as diagnosis is made, initiate ONE of:
- IVIG 2 g/kg total, divided over 2-5 days, OR
- Plasma exchange (PLEX): 5-6 total plasma volume exchanges over 10-14 days
Neither has been proven superior to the other — selection based on availability, access (PLEX requires large-bore access and specialized equipment), and patient factors (IgA deficiency is a PLEX consideration if IVIG contraindicated for that reason, and vice versa).
"Stacking" (combining both) provides NO proven additional benefit. CRITICAL SEQUENCING RULE: avoid using PLEX AFTER IVIG — plasma exchange will physically remove the IVIG that was just administered, eliminating its therapeutic effect. If both are being considered, PLEX should precede IVIG, not follow it.
Corticosteroids have NO role in GBS treatment — despite the autoimmune/inflammatory pathophysiology, steroids have not shown benefit and should not be used as primary or adjunctive therapy.
7. Prognosis
Many patients have near-complete recovery. Residual disability more likely with: diarrheal prodrome, older age, severe weakness, need for mechanical ventilation, and evidence of axon loss on EMG/NCS (axonal variants generally carry worse prognosis than pure demyelinating AIDP).
Modified Erasmus GBS Outcome Score (mEGOS): internationally validated prediction model, applicable early in the disease course, predicts probability of being unable to walk independently at 6 months — accessible via online calculators, useful for family counseling and rehabilitation planning discussions early rather than waiting for the clinical course to fully declare itself.
No evidence supports retreatment with IVIG or PLEX for less-than-desired outcomes — avoid repeating therapy reflexively if initial response is suboptimal; this is not an evidence-supported escalation strategy.
8. Organ Support
Mechanical ventilation per respiratory failure criteria (early intubation favored, Section 4); autonomic dysfunction management (Section 5); nutrition (enteral, given bulbar involvement risk requires careful swallow assessment); DVT prophylaxis (immobility risk); bowel/bladder management for autonomic dysfunction (ileus, urinary retention).
9. Consultation Matrix
Consultation | Trigger | Timing |
Neurology | All suspected/confirmed GBS | Immediate |
Neurocritical Care / ICU | Respiratory failure, autonomic instability | Immediate |
Palliative Care | Symptom management (cramps, spasticity, sialorrhea, constipation, depression/anxiety), goals-of-care support during prolonged ventilator course | As needed, can be proactive |
Physical/Occupational Therapy | Early, given prolonged recovery trajectory | Early in admission |
10. Monitoring Framework
Serial neuro exams (eyes, bulbar, limb strength, reflexes), respiratory parameters (vital capacity, NIF trending, EGRIS reassessment), continuous cardiac monitoring for autonomic instability, bowel/bladder function monitoring, watch for tracheostomy need trajectory (~50% of ventilated patients).
11. Complications
Respiratory failure, autonomic dysfunction (labile BP, arrhythmia, ileus, urinary retention), aspiration (bulbar weakness), VAP/nosocomial infection (prolonged ventilation), DVT/PE (immobility), ICU-acquired weakness compounding underlying GBS weakness, pain/dysesthesias, psychological distress (locked-in-like experience in severe cases while cognitively intact). Prevention: early intubation before crisis, cautious BP management, atropine availability, DVT prophylaxis, early PT/OT and psychological support. Rescue: standard ICU respiratory/hemodynamic support; there is no rescue pharmacotherapy beyond IVIG/PLEX already given — supportive care carries the patient through the monophasic course.
12. Escalation & De-escalation
Escalate: declining respiratory parameters/EGRIS trajectory -> early intubation (do not wait for NIV failure if still progressing toward nadir); autonomic instability -> continuous monitoring, cautious BP management.
De-escalate: past nadir (per the 2-4 week definitional window), improving strength -> begin ventilator weaning/SBTs, wean autonomic monitoring intensity as stability returns, transition to rehabilitation-focused care.
13. ICU Discharge Criteria
Respiratory status stable/improving (extubated or on a defined tracheostomy weaning trajectory), autonomic instability resolved/managed, past the disease nadir with documented improvement trend, rehabilitation plan established, psychological/palliative support needs addressed.
14. Documentation & Medicolegal Checklist
15. Key Guidelines
Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683 — primary contemporary reference.
16. Landmark Evidence
Doets AY, Lingsma HF, Walgaard C, et al. Predicting outcome in GBS: international validation of the modified Erasmus GBS Outcome Score. Neurology. 2022;98(5):e518-e532 — mEGOS validation.
17. Controversies
IVIG vs PLEX selection lacks head-to-head superiority evidence — choice remains institution/access-driven rather than evidence-mandated. The precise threshold for "early/prophylactic" intubation vs a brief NIV trial is not rigidly defined — the general principle (intubate early if still progressing toward nadir) is pattern-based clinical wisdom more than a validated algorithm. Retreatment strategies for poor responders remain unsupported by evidence, leaving a genuine management gap for this subgroup.
18. References
- Neuromuscular Respiratory Failure / Guillain-Barré Syndrome chapter. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 62).
- Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683.
- Doets AY, Lingsma HF, Walgaard C, et al. Predicting outcome in Guillain-Barré syndrome: international validation of the modified Erasmus GBS Outcome Score. Neurology. 2022;98(5):e518-e532.
- Bucelli R, Harms MB. Neuromuscular emergencies. Semin Neurol. 2015;35(6):683-689.
- Amato AA, Russell JA. Neuromuscular Disorders. 2nd ed. McGraw Hill; 2015.
See also: Myasthenic Crisis (Neurology System) for the contrasting fluctuating-weakness neuromuscular respiratory failure pattern and NIV-trial-appropriate approach.